Xcelience eyes EU growth; DSM inks deal with Paranta;

> After opening a new plant in Florida, Xcelience is looking to boost its EU trial supply business. Article

> DSM Pharmaceutical has inked a deal with Paranta Biosciences for process development and cGMP manufacture of Follistatin, the company's lead recombinant human protein. News

> Althea Technologies has won a contract to manufacture a circumsporozoite protein for Pfenex's malaria vaccine. Story

> Penn Pharma recently completed a new solid oral dose facility, and the company says it's in talks with Big Pharma on potential partnerships. More

> AMRI has extended its extended its supply agreement with Shire ($SHPG) for another 5 years. Item

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.